MicroRNAs as cancer therapeutics : A step closer to clinical application
Catela Ivkovic, Tina LU ; Voss, Gjendine LU ; Cornella, Helena LU and Ceder, Yvonne LU
(2017)
In Cancer Letters
407.
p.113-122
- Abstract
During the last decades, basic and translational research has enabled great improvements in the clinical management of cancer. However, scarcity of complete remission and many drug-induced toxicities are still a major problem in the clinics. Recently, microRNAs (miRNAs) have emerged as promising therapeutic targets due to their involvement in cancer development and progression. Their extraordinary regulatory potential, which enables regulation of entire signalling networks within the cells, makes them an interesting tool for the development of cancer therapeutics. In this review we will focus on miRNAs with experimentally proven therapeutic potential, and discuss recent advances in the technical development and clinical evaluation of... (More)
During the last decades, basic and translational research has enabled great improvements in the clinical management of cancer. However, scarcity of complete remission and many drug-induced toxicities are still a major problem in the clinics. Recently, microRNAs (miRNAs) have emerged as promising therapeutic targets due to their involvement in cancer development and progression. Their extraordinary regulatory potential, which enables regulation of entire signalling networks within the cells, makes them an interesting tool for the development of cancer therapeutics. In this review we will focus on miRNAs with experimentally proven therapeutic potential, and discuss recent advances in the technical development and clinical evaluation of miRNA-based therapeutic agents.
(Less)
- author
- Catela Ivkovic, Tina
LU
; Voss, Gjendine
LU
; Cornella, Helena
LU
and Ceder, Yvonne
LU
- organization
- publishing date
- 2017-02-16
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Drug delivery, Metastases, MiR-15/16, MiR-155, MiR-34a, Therapy resistance
- in
- Cancer Letters
- volume
- 407
- pages
- 113 - 122
- publisher
- Elsevier
- external identifiers
-
- pmid:28412239
- wos:000412379800012
- scopus:85018738027
- ISSN
- 0304-3835
- DOI
- 10.1016/j.canlet.2017.04.007
- language
- English
- LU publication?
- yes
- id
- 0c6388f5-60d9-4418-8df2-371f1e8e06a6
- date added to LUP
- 2017-06-14 15:21:55
- date last changed
- 2024-04-14 12:30:47
@article{0c6388f5-60d9-4418-8df2-371f1e8e06a6,
abstract = {{<p>During the last decades, basic and translational research has enabled great improvements in the clinical management of cancer. However, scarcity of complete remission and many drug-induced toxicities are still a major problem in the clinics. Recently, microRNAs (miRNAs) have emerged as promising therapeutic targets due to their involvement in cancer development and progression. Their extraordinary regulatory potential, which enables regulation of entire signalling networks within the cells, makes them an interesting tool for the development of cancer therapeutics. In this review we will focus on miRNAs with experimentally proven therapeutic potential, and discuss recent advances in the technical development and clinical evaluation of miRNA-based therapeutic agents.</p>}},
author = {{Catela Ivkovic, Tina and Voss, Gjendine and Cornella, Helena and Ceder, Yvonne}},
issn = {{0304-3835}},
keywords = {{Drug delivery; Metastases; MiR-15/16; MiR-155; MiR-34a; Therapy resistance}},
language = {{eng}},
month = {{02}},
pages = {{113--122}},
publisher = {{Elsevier}},
series = {{Cancer Letters}},
title = {{MicroRNAs as cancer therapeutics : A step closer to clinical application}},
url = {{http://dx.doi.org/10.1016/j.canlet.2017.04.007}},
doi = {{10.1016/j.canlet.2017.04.007}},
volume = {{407}},
year = {{2017}},
}